Hepatitis C, interferon alpha and psychiatric co-morbidity in intravenous drug users (IVDU): Guidelines for clinical practice

Acta Gastro-Enterologica Belgica

Volumn 68, Issue 1, 2005, Pages 68-80

  De Bie, J ^a   Robaeys, G ^a   Buntinx, F ^b  

^a DEPARTMENT OF CARDIOLOGY   (Belgium)

^b Campus Sint Jan ^*

Author keywords

Co morbidity; Depression; Hepatitis C; Interferon; Intravenous drug abuse; Psychiatry; Therapy

Indexed keywords

ALCOHOL; ALPHA INTERFERON; ALPRAZOLAM; AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CANNABIS; CITALOPRAM; COCAINE; DOXEPIN; FLUOXETINE; ILLICIT DRUG; IMIPRAMINE; METHADONE; MIRTAZAPINE; NEFAZODONE; OPIATE; PAROXETINE; PEGINTERFERON; SEDATIVE AGENT; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SULPIRIDE;

ANXIETY DISORDER; BECK DEPRESSION INVENTORY; BEHAVIOR DISORDER; BRAIN DYSFUNCTION; CLINICAL PRACTICE; CLINICAL TRIAL; COMORBIDITY; CONFERENCE PAPER; DEPRESSION; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG DEPENDENCE; DRUG DOSE REGIMEN; FATIGUE; FLU LIKE SYNDROME; HEPATITIS C; HIGH RISK PATIENT; HUMAN; IMMUNE RESPONSE; INTRAVENOUS DRUG ABUSE; IRRITABILITY; MAJOR DEPRESSION; MANIA; MENTAL DISEASE; META ANALYSIS; METHADONE TREATMENT; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; PANIC; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PSYCHOSIS; RATING SCALE; RISK FACTOR; SCORING SYSTEM; SEIZURE; SIDE EFFECT; SUICIDE ATTEMPT; SYMPTOM; SYSTEMATIC REVIEW;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ANTIDEPRESSIVE AGENTS; ANTIVIRAL AGENTS; BEHAVIOR THERAPY; BELGIUM; COMORBIDITY; DEPRESSIVE DISORDER; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NETHERLANDS; PRACTICE GUIDELINES; PROGNOSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX DISTRIBUTION; SUBSTANCE ABUSE, INTRAVENOUS; TREATMENT OUTCOME;

EID: 16444361834     PISSN: 00015644     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (97)

1. DIEPERINK E., WILLENBRING M., HO S.B. Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: A Review. Am. J. Psychiatry, 2000, 157: 867-876.
2. SULLIVAN L.E., FIELLIN D.A. Hepatitis C and HIV Infections: Implications for Clinical Care in Injection Drug Users. Am. J. Addict., 2004, 13: 1-20.
3. EDLIN B.R., SEAL K.H., LORVICK J. Is it justifiable to withhold treatment for hepatitis C from illicit-drug users? N. Engl. J. Med., 2001, 345: 211-213.
4. JOWETT S.L., AGARWAL K., SMITH B.C., CRAIG W., HEWETT M., BASSENDINE D.R., GILVARRY E., BURT A.D., BASSENDINE M.F., Managing chronic hepatitis C acquired through intravenous drug use. Q. J. Med., 2001, 94: 153-158.
5. CHEUNG R., AHMED A. Treating chronic hepatitis C patients with psychiatric disorders: an uphill battle. Am. J. Gastroenterol., 2000, 96: 3-4.
6. FALCK-YTTER Y., KALE H., MULLEN K.D., SARBAH S.A., SORESCU L., MC CULLOUGH A.J. Surprisingly small effect of antiviral treatment in Patients with hepatitis C. Ann. Intern. Med., 2002, 136: 288-292.
7. ROWAN P.J., TABASI S., ABDUL-LATIF M., KUNIK M.E., EL-SERAG H.B. Psychosocial factors are the most common contraindications for antiviral therapy at initial evaluation in veterans with chronic hepatitis C. Clin. Gastroenterol., 2004, 38: 530-534.
8. SCHAEFER M., HEINZ A., BACKMUND M. Treatment of chronic hepatitis C in patients with drug dependence: time to change the rules? Addiction, 2004, 99: 1167-1175.
9. STRADER D.B.W., WRIGHT T., THOMAS D.L., SEEF L.B. Diagnosis Management and treatment of Hepatitis C. Hepatology, 2004, 39: 1147-1171.
10. VANDERSCHUEREN S., VAN RENTERGHEM L., PLUM J., VERHOFSTEDE C., MAK R., VINCKE J. Hepatitis C among risk groups for HIV and hepatitis B. Int. J. STD. AIDS, 1991, 2: 185-187.
11. APICHARTPIYAKUL C., APICHARTPIYAKUL N., URWIJITAROON Y., GRAY J. NATPRATAN C., KATAYAMA Y., FUJII M., HOTTA H. Seroprevalence and subtype distribution of hepatitis C virus among blood donors and intravenous drug users in northern/northeastern Thailand. Jpn. J. Infect. Dis., 1999, 52: 121-123.
12. VAN DAMME P., THYSSEN A., VAN LOOCK F. Epidemiology of hepatitis C in Belgium: present and future. Acta Gastroenterol. Belg., 2002, 65: 78-79.
13. MILLER NS. Co morbidity of psychiatric and alcohol/drug disorders: interactions and independent status. J. Addict. Dis., 1993, 12: 5-16.
14. MERIKANGAS K.R., MEHTA R.L., MOLNAR B.E., WALTERS E.E., SWENDSEN J.D., AGUILAR-GAZIOLA S., BIJL R., BORGES G., CARAVEO-ANDUAGA J.J., DE WIT D.J., KOLODY B., VEGA W.A., WITTCHEN H.U., KESSLER R.C. Co morbidity of substance use disorders with mood and anxiety disorders: results of the international consortium in psychiatric epidemiology. Addict. Behav., 1998, 23: 893-907.
15. BROONER R.K., BIGELOW G.E., STRAIN E., SCHMIDT C.W. Intravenous drug abusers with antisocial personality disorder: increased HIV risk behaviour. Drug Alcohol Depend., 1990, 26: 39-44.
16. BROONER R.K., GREENFIELD L., SCHMIDT C.W., BIGELOW G.E. Antisocial personality disorder and HIV infection among intravenous drug users. Am. J. Psychiatry, 1993, 50: 53-58.
17. DINWIDDIE S.H., REICH T., CLONINGER C.R. Psychiatric co morbidity and suicidality among intravenous drug users. J. Clin. Psychiatry, 1992, 53: 364-369.
18. LIPSITZ J.D., WILLIAMS J.B.W., RABKIN J.G., REMIEN R.H., BRADBURY M., EL SADR W., GOETZ R., SORRELL S., GORMAN J.M. Psychopathology in male and female intravenous drug users with and without HIV infection. Am. J. Psychiatry. 1994, 151: 1662-1668.
19. KRAUSZ M., VERTHEIN U., DEGKWITZ P. Prevalence of psychiatric disorders in opiate dependent patients in contact with the drug treatment system. Nervenarzt, 1998, 69: 557-67.
20. MILBY J.B., SIMS M.K., KHUDER S., SCHUMACHER J.E., HUGGINS N., MC LELLAN A.T., WOODY G., HAAS N. Psychiatric co morbidity: prevalence in methadone maintenance treatment. Am. J. Drug Alcohol Abuse, 1996, 22: 95-107.
21. FREI A., REHM J. The prevalence of psychiatric co-morbidity among opioid addicts. Psychiatr. Prax., 2002, 29: 258-62.
22. VAN THIEL D.H., ANANTHARAJU A., CREECH S. Response to Treatment of Hepatitis C in Individuals With a recent History of Intravenous Drug Abuse. Am. J. Gastroenterology, 2003, 98: 2281-2288.
23. ROUNSAVILLE B.J., PETRY M.J., CARROL K.M. Single versus multiple drug focus in substance abuse clinical trials research. Drug and Alcohol Dependence, 2003, 70: 117-125.
24. JOHNSON M.E., FISHER D.G., FENAUGHTY A., THENO S.A. Hepatitis C virus and depression in drug users. Am. J. Gastroenterology, 1998, 93: 785-789.
25. GRASSI L., SATRIANO J., SERRA A., BIANCOSINO B., ZOTO S., SIGHINOLFI L., GHINELLI F. Emotional stress, psychosocial variables and coping associated with hepatitis C and human immunodeficiency virus infection in intravenous drug users. Psychother. Psychosom., 2002, 71: 342-349.
26. EL-SERAG H.B., KUNIK M., RICHARDSON P., RABENECK L. Psychiatric disorders among veterans with hepatitis C infection. Gastroenterology, 2002, 123: 476-482.
27. WESSELY S., PARIANTE C. Fatigue, depression and chronic hepatitis C infection. Psychol. Med., 2002, 32: 1-10.
28. WEISSENBORN K., KRAUSE J., BOKEMEYER M., HECKER H., SCHULER A., ENNEN J. C., AHL B., MANNS M.P., BOKER K.W. Hepatitis C virus infection affects the brain-evidence from psychometric studies and magnetic resonance spectroscopy. J. Hepatol., 2004, 41: 845-851.
29. FORTON D.M., ALLSOP J.M., MAIN J., FOSTER G.R., THOMAS H.C., TAYLOR-ROBINSON S.D. Evidence for a cerebral effect of the hepatitis C virus. Lancet, 2001, 358: 38-39.
30. FORTON D.M., TAYLOER-ROBINSON S.D., THOMAS H.C. Cerebral dysfunction in chronic hepatitis C infection. J. Viral Hepat., 2003, 10: 81-86.
31. KRAMER L., BAUER E., FUNK G., HOGER H., JESSNER W., STEINDL-MUNDA P., MADL C., GANGL A., FERENCI P. Sub clinical impairment of brain function in chronic hepatitis C infection. J. Hepatol., 2002, 37: 349-354.
32. RYAN E.L., MORGELLO S., ISAACS K., NASEER M., GERITS P. The Manhattan Bank. Neuropsychiatric impact of hepatitis C on advanced HIV. Neurology, 2004, 62: 957-962.
33. DALGARD O., EGELAND A., SKAUG K., VILIMAS K., STEEN T. Health-related quality of life in active injecting drug users with and without chronic hepatitis C virus infection. Hepatology, 2004, 39: 74-80.
34. HAUSER W., ZIMMER C., SCHIEDERMAIER P., GRANDT D. Biopsychosocial Predictors of Health-Related Quality of Life in Patients with Chronic Hepatitis C. Psychosomatic Medicine, 2004, 66: 954-958.
35. MULDER R.T., ANG M., CHAPMAN B., ROSS A., STEVENS I.F., EDGAR C. Interferon Treatment is not associated with a worsening of psychiatric symptoms in patients with hepatitis C. Journal of Gastroenterology and Hepatology, 2000, 15: 300-303.
36. KRAUS M.R., SCHAEFER A., CSEF H., SCHEURLEN M., FALLER H. Emotional State, Coping Styles and Somatic Variables in Patients with Chronic Hepatitis C. Psychosomatics, 2000, 41: 377-384.
37. YOVTCHEVA S.P., RIFAI M.A., MOLES J.K., VAN DER LINDEN B.J. Psychiatric co morbidity among hepatitis C-positive patients. Psychosomatics, 2001, 42: 411-415.
38. GRASSI L., MONDARDINI D., FAVANATI M., SIGHINOLFI L., SERRA A., GHINELLI F. Suicide probability and psychological morbidity secondary to HIV infection: a control study of HIV-seropositive, hepatitis C virus (HCV)-seropositive and HIV/HCV-seronegative injecting drug users. J. Affect. Disord., 2001, 64: 195-202.
39. GOLUB E.T., LATKA M., HAGAN H., HAVENS J.R., HUDSON S.M., KAPADIA F., CAMPBELL J.V., GARFEIN R.S., THOMAS D.L., STRATHDEE S.A. Screening for Depressive Symptoms Among HCV-infected Injection Drug Users: Examination of the Utility of the CES and the Beck Depression Inventory. J. Urban Health, 2004, 81: 278-290.
40. NOLEN W.A., DINGEMANS P.M.A.J. Meetinstrumenten bij stemmings- stoornissen. Tijdschrift voor Psychiatrie, 2004, 46: 681-685.
41. RADLOFF L.S. The CES-D scale: A self report Depression Scale for Research in the General Population. Applied Psychological Measurement, 1977, 1: 385-401.
42. ZIGMOND A.S., SNAITH R.P. The Hospital Anxiety and Depression Scale. Acta Psychiatrica Scandinavica, 1983, 67: 361-370.
43. SPINHOVEN P., ORMEL J., SLOEKERS P.P., KEMPEN G.I., SPECKENS A.E., VAN HEMERT A.M. A validation study of the Hospital Anxiety and Depression scale (HADS) in different groups of Dutch subjects. Psychological Medicine, 1997, 27: 363-370.
44. BECK A.T., WARD C.H., MENDELSON M., MOCK J., ERBAUGH J. An inventory for measuring depression. Arch. Gen. Psychiatry, 1961, 4: 561-571.
45. BOUMAN T.K., LUTEIJN F., ALBERTNAGEL F.A., VAN DER PLOEG F.A. Enige ervaringen met de Beck Depression Inventory. Gedrag Tijdsch. Psych., 1985, 13: 13-24.
46. ZUNG W.W.J., RICHARDS C.B., SHORT M.J. Self-rating depression scale in an outpatient clinic. Arch. Gen. Psychiatry, 1965, 13: 508-513.
47. ZIMMERMAN M., CORYELL W. The Inventory to diagnose depression (IDD): a self-report scale to diagnose major depressive disorder. J. Consult. Clin. Psychol., 1987, 55: 55-59.
48. WATSON D., CLARK L.A., TELLEGEN A. Development and validation of brief measures of positive and negative affect: the PANAS scales. J. Pers. Soc. Psychol., 1988, 54: 1063-1070.
49. WARE J. SF-3 Health Survey: Manual and Interpretation Guide. Boston, New England Medical Centre, Health Institute, 1998.
50. DEROGATIS L.R., LIPMAN R.S., COVI L. SCL-90: An outpatient psychiatric rating scale - preliminary report. Psychopharmacology Bull., 1973, 9: 13-28.
51. MONTGOMERY S.A., ASBERG M. A new depression scale designed to be sensitive to change. Br. J. Psychiatry, 1979, 134: 382-389.
52. HAMILTON M. A Rating scale for depression. J. Neurol. Neurosurg. Psychiatry, 1960, 23: 56-62.
53. DIEPERINK E., HO S.B., THURAS P., WILLENBRING M.L. A prospective study of neuropsychiatric symptoms associate with interferon-alpha-2b and Ribavirin Therapy for Patients with Chronic Hepatitis C. Psychosomatics, 2003, 44: 104-112.
54. RENAULT P.P., HOOFNAGLE J.H., PARK Y., MULLEN K.D., PETERS M., JONES D.B., RUSTGI V., JONES E.A. Psychiatric Complications of long term Interferon Alfa Therapy. Arch. Intern. Med., 1987, 147: 1577-1580.
55. MC DONALD E.M., MANN A.H., THOMAS H.C. Interferon as mediators of psychiatric morbidity. An investigation in a trial of recombinant alpha interferon in hepatitis-B carriers. Lancet, 1987, 2 (8569): 1175-1177.
56. VAN THIEL D.H., FRIEDLANDER L., MOLLOY P.J., FAGIUOLI S., KANIA R.J., CARACENI P. Interferon alpha can be used successfully in patients with hepatitis C positive chronic hepatitis who have a psychiatric illness. Eur. J. Gastroenterol. Hepatol., 1995, 7: 165-168.
57. BOURAT L., LARREY D., MICHEL H. Tentative de suicide lors du traitement d'une hepatite chronique virale C par interféron. A propos de 2 cas. Gastroenterol. Clin. Biol., 1995, 19: 1063.
58. TARUSCHIO G., SANTARINI I., SICA G et al. Psychiatric disorders in hepatitis C related chronic liver disease. Gastroenterology, 1996, 110: A1342.
59. FATTOVICH G., GIUSTINA G., FAVARATO S.A. A survey of adverse events in 11241 patients with chronic viral hepatitis with alfa interferon. J. Hepatol., 1996, 24: 38-47.
60. HUNT C.M., DOMINITZ J.A., BUTE B.P., WATERS B., BLASI U., WILLIAMS D.M. Effect of Interferon-alpha Treatment of Chronic Hepatitis C on Health-Related Quality of Life. Dig. Dis. Sci., 1997, 42: 2482-2486.
61. NERI S., BRUNO C.L., ABATE G., IERNA D., MAUCERI B., CILIO D., BORDONARO F., PULVIRENTI D., ITALIANO C., CARUSO L. Controlled clinical trial to assess the response of recent heroin abusers with chronic hepatitis C virus infection to treatment with interferon alpha-n2b. Clin. Therapeutics, 2002, 24: 1627-1635.
62. OTSUBO T., MIYAOKA H., KAMIJIMA K., ONUKI M., ISHII M., MITAMURA K. Depression during interferon therapy in chronic hepatitis C patients - a prospective study. Seishin Shinkeigaku Zasshi, 1997, 99: 101-127.
63. HEERINGA M., HONKOOP P., DE MAN R.A., FEENSTRA J., SMITS C.M. Major psychiatric side effects of interferon alpha 2 b. Ned. Tijdschr. Geneesk., 1998, 142: 1618-1621.
64. MALAGUARNERA M., DI FAZIO I, RESTUCCIA S., PISTONE G., FERLITO L., RAMPELLO L. Interferon alpha-induced depression in chronic hepatitis C patients, comparison between different types of interferon alpha. Neuropsychobiology, 1998, 37: 93-97.
65. YATES W.R., GLEASON O. Hepatitis C and Depression. Depression and Anxiety, 1998, 7: 188-193.
66. VAN THIEL D.H., FRIEDLANDER L., DE MARIA N., MOLLOY P.J., KANIA R.J., COLANTONI A. Treatment of Chronic Hepatitis C in Individuals with Pre-existing or Confounding Neuropsychiatric disease. Hepato-gastroenterology, 1998, 45: 328-330.
67. PARIANTE C.M., ORRU M.G., BAITA A., FARCI M.G., CARPINIELLO B. Treatment with interferon-alpha in patients with chronic hepatitis and mood or anxiety disorders. Lancet, 1999, 354 (9173): 131-132.
68. PARIANTE C.M., LANDAU S., CARPINIELLO B. Interferon Alfa-induced Adverse Effects in patients with a psychiatric diagnosis. N. Engl. J. Med., 1999, 347: 148-149.
69. MIYAOKA H., OTSUBO T., KAMIJIMA K., ISHII M., ONUKI M., MITAMURA K. Depression from interferon therapy in patients with hepatitis C. Am. J. Psychiatry, 1999, 156: 1120.
70. SCALORI A., APALE P., PANIZUTTI F., MASCOLI N., PIOLTELI P., POZZI M., REDAELLI A., ROFFI L., MANCIA G. Depression during interferon therapy for chronic viral hepatitis: early identification of patients at risk by means of a computerized test. Eur. J. Gastroenterol. Hepatol., 2000, 12: 505-509.
71. SCHAEFER M., BOETSCH T., LAAKMANN G. Psychosis in a methadone-substituted patient during interferon-alpha treatment of hepatitis C. Addiction, 2000, 95: 1101-1104.
72. BACKMUND M., MEYER K., VON ZIELONKA M., EICHENLAUB D. Treatment of hepatitis C infection in injection drug users. Hepatology, 2001, 34: 188-193.
73. HO S.B., NGUYEN H., TETRICK L.L., OPITZ G.A., BASARA M.L., DIEPERINK E. Influence of Psychiatric Diagnoses on Interferon-alpha Treatment for Chronic Hepatitis C in a Veteran Population. Am. J. Gastroenterol., 2001, 96: 157-164.
74. HAUSER P., KHOSLA J., AURORA H., LAURIN J., KLING M.A., HILL J., GULATI M., THORNTON A.J., SCHULTZ R.L., VALENTINE A.D., MEYERS C.A., HOWELL C.D. A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol. Psychiatry, 2002, 7: 942-947.
75. PARIANTE C.M., LANDAU S., CARPINIELLO B., CAGLIARI GROUP. Interferon alfa-induced adverse events in patients with a psychiatric diagnosis. N. Engl. J. Med., 2002, 347: 148-149.
76. KOSKINAS J., MERKOURAKI P., MANESIS E., HADZIYANNIS S. Assessment of depression in patients with chronic hepatitis: effect of interferon treatment. Dig. Dis., 2002, 20: 284-288.
77. SYLVESTRE D.L. Treating hepatitis C in methadone maintenance patients: an interim analysis. Drug Alcohol Depend., 2002, 67: 117-123.
78. BONACCORSO S., MARINO V., BIONDI M., GRIMALDI F., IPPOLITI F., MAES M. Depression induced by treatment with interferon-alpha in patients affected by hepatitis C virus. J. Affect. Disord., 2002, 72: 237-241.
79. SCHAEFER M., SCHMIDT F., FOLWACZNY C., LORENZ R., MARTIN G., SCHINDLBECK N., HELDWEIN W., SOYKA M., GRUNZE H., KOENIG A., LOESCHKE K. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology, 2003, 37: 443-451.
80. SUZUKI E., YOSHIDA Y., SHIBUYA A., MIYAOKA H. Nitric oxide involvement in depression during interferon-alpha therapy. Int. J. Neuropsychopharmacol., 2003, 6: 415-419.
81. GALLEGOS-OROZCO I.F., FUENTES A.P., GERARDO ARGUETA I., PEREZ-PRUNA C., HINOJOSA-BECERRIL C., SIXTOX-ALONSO M.S., CRUZ-CASTELLANOS S., GUTIERREZ-REYES G., OLIVERA-MARTINEZ M.A., GUTIERREZ-RUIZ M.C., KERSHENOBICH D. Health-related quality of life and depression in patients with chronic hepatitis C. Arch. Med. Res., 2003, 34: 124-129.
82. KRAUS M.R., SCHAFER A., FALLER H., CSEF H., SCHEURLEN M. Psychiatric Symptoms in Patients with Chronic Hepatitis C Receiving Interferon Alfa-2b Therapy. J. Clin. Psychiatry, 2003, 64: 708-714.
83. HORIKAWA N., YAMAZAKI T., IZUMI N., UCHIHARA M. Incidence and Clinical course of major depression in patients with chronic hepatitis type C undergoing interferon-alpha therapy: a prospective study. General Hospital Psychiatry, 2003, 25: 34-38.
84. GOHIER B., GOEB J.L., RANNOU-DUBAS K., FOUCHARD I., CALES P., GARRE J.B. Hepatitis C, alpha interferon, anxiety and depression disorders: a prospective study of 71 patients. World J. Biol. Psychiatry, 2003, 4: 115-118.
85. GOCHEE P.A., POWELL E.E., PURDIE D.M., PANDEYA N., KELEMEN L., SHORTHOUSE C., JONSSON J.R., KELLY B. Association between apolipoprotein E epsilon 4 and Neuropsychiatric symptoms during interferon alpha treatment for chronic hepatitis C. Psychosomatics, 2004, 45: 49-57.
86. WICHERS M.C., KOEK G.H., ROBAEYS G., PRAAMSTRA A.J., MAES M. Early Increase in Vegetative Symptoms predicts IFN-alpha-induced Cognitive-Depressive Changes. Psychological Medicine, 2005 (in press).
87. MAUSS S., BERGER F., GOELZ J., JACOB B., SCHMUTZ G. A prospective controlled study of interferon-based therapy of hepatitis C in patients on methadone maintenance. Hepatology, 2004, 40: 120-124.
88. CAPURON L., RAVAUD A. Prediction of the Depressive Effects of Interferon Alfa Therapy by the Patient's Initial Affective State. N. Engl. J. Med., 1999, 340: 17: 1370.
89. LOFTIS J.M., SOCHERMAN R.E., HOWELL C.D., WHITEHEAD A.J., HILL J.A., DOMINITZ J.A., HAUSER P. Association of interferon-alpha induced depression and improved treatment response in patients with hepatitis C. Neuroscience Letters, 2004, 365: 87-91.
90. FONTANA R.J. Neuropsychiatric toxicity of antiviral treatment in chronic hepatitis C. Dig. Dis., 2000, 18: 107-116.
91. SCHRAMM T.M., LAWFORD B.R., MACDONALD G.A., COOKS W.G.E. Sertraline treatment of interferon-alfa-induced depressive disorder. MJA, 2000, 173: 359-361.
92. GLEASON O.C., YATES W.R. Five cases of interferon alpha induced depression treated with antidepressant therapy. Psychosomatics, 1999, 40: 510-512.
93. GLEASON O.C., YATES W.R., ISBELL M.D., PHILIPSEN M.A. An open-label trial of citalopram for major depression in patients with hepatitis C. J. Clin. Psychiatr., 2002, 63: 194-198.
94. KRAUS M.R., SCHAEFER A., FALLER H., CSEF H., SCHEURLEN M. Paroxetine for the treatment of interferon - alpha-induced depression in chronic hepatitis C. Aliment. Pharmacol. Ther., 2002, 16: 1091-1099.
95. LANG J.P., MICHEL L., HALLEGUEN O. Treatment of affective disorder in hepatitis C. A prospective study in 50 patients. Ann. Med. Interne (Paris), 2002, 153 (Suppl): 2S22-30.
96. MALEK-AHMADI P., GHANDOUR E. Bupropion for Treatment of Interferon-induced Depression. The Annals Online, 2004: 18 May, 2004.
97. GALLUCCI G., SMOLINSKI J. Treatment Contracts for Patients with Hepatitis C, Psychiatric Illness and Substance abuse, Psychosomatics, 2001, 42: 353-355.